Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002871-32
    Sponsor's Protocol Code Number:D3255C00001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-08-31
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-002871-32
    A.3Full title of the trial
    A Multicenter, Randomized, Double-blind, Parallel-group, Placebocontrolled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA)
    Studio multicentrico, randomizzato, in doppio cieco, a gruppi paralleli, controllato con placebo, volto a esaminare l’uso di benralizumab per l’esofagite eosinofila (MESSINA)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of Benralizumab in Patients with Eosinophilic Esophagitis
    Studio con Benralizumab in pazienti con esofagite eosinofila
    A.3.2Name or abbreviated title of the trial where available
    MESSINA
    MESSINA
    A.4.1Sponsor's protocol code numberD3255C00001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorASTRAZENECA AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca AB
    B.5.2Functional name of contact pointInformation Center
    B.5.3 Address:
    B.5.3.1Street Addressna
    B.5.3.2Town/ citySodertalje
    B.5.3.3Post codeSE-15185
    B.5.3.4CountrySweden
    B.5.4Telephone number0000000000
    B.5.5Fax number000000000000
    B.5.6E-mailinformation.center@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebenralizumab
    D.3.2Product code [MEDI-563]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNbenralizumab
    D.3.9.1CAS number 1044511-01-4
    D.3.9.2Current sponsor codeMEDI-563
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Eosinophilic Esophagitis (EoE)
    Esofagite Eosinofila (EoE)
    E.1.1.1Medical condition in easily understood language
    Eosinophilic Esophagitis (EoE)
    Allergic Esophagitis
    Esofagite Eosinofila (EoE)
    Esofagite Allergica
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10064220
    E.1.2Term Eosinophilic esophagitis
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of benralizumab Dose Regimen 1 on histologic signs and symptoms of EoE in patients with symptomatic and histologically active EoE.
    Valutare l’effetto di Benralizumab al Regime di Dose 1 sui segni istologici e sui sintomi dell’ Esofagite eosinofila in pazienti con Esofagite Eosinofila sintomatica ed istologicamente attiva.
    E.2.2Secondary objectives of the trial
    DB treatment period:
    - To evaluate the effect of benralizumab Dose Regimen 1 on clinical features of EoE and disease activity.
    - To evaluate the effect of benralizumab Dose Regimen 1 on patient reported QOL measures.
    - To evaluate the effect of benralizumab Dose Regimen 1 on healthcare resource utilization due to EoE.
    - To evaluate the effect of benralizumab Dose Regimen 1 on patient reported measures of disease severity and health status.
    - To assess the PK and immunogenicity of benralizumab Dose Regimen 1 in patients with EoE.
    - To assess the safety and tolerability of benralizumab Dose Regimen 1 in patients with EoE.
    Periodo di trattamento in doppio cieco:
    - Valutare l’effetto di Benralizumab al Regime di Dose 1 sulle caratteristiche cliniche dell’ Esofagite eosinofila e sull’attività della patologia.
    - Valutare l’effetto di Benralizumab al Regime di Dose 1 sulle misure di QOL riportate dai pazienti.
    - Valutare l’effetto di Benralizumab al Regime di Dose 1 sull’utilizzo delle risorse del sistema sanitario a causa dell’ Esofagite eosinofila.
    - Valutare l’effetto di Benralizumab al Regime di Dose 1 sulle misure di gravità della patologia e stato di salute riportate dai pazienti.
    - Stimare la PK ed immunogenicità di Benralizumab al Regime di Dose 1 in pazienti con Esofagite eosinofila.
    - Stimare la sicurezza e tollerabilità di Benralizumab al Regime di Dose 1 in pazienti con Esofagite eosinofila.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: EndoFLIP (Endolumenal Functional Lumen Imaging Probe)
    Objective: To evaluate the effect of benralizumab dose regimen 1 on clinical features pf EoE and diesease activity

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: EndoFLIP (Endolumenal Functional Lumen Imaging Probe)
    Obiettivo: Valutare l'effetto del regime di dosaggio 1 di benralizumab sulle caratteristiche cliniche della EoE e sull'attività della malattia
    E.3Principal inclusion criteria
    - Patients 12 to 65 years of age, inclusive, at the time of signing the informed consent or assent (if applicable) form.
    - Documented previous diagnosis of EoE by endoscopy (documented diagnosis defined as an esophageal count of =15 eos/hpf on at least 1 esophageal level) and confirmed diagnosis by a centrally-read esophageal biopsy for the purposes of this study (confirmed diagnosis defined as an esophageal count of =15 eos/hpf at 2 or more esophageal levels). Two to 4 biopsies should be obtained from both the proximal and distal esophagus. Biopsies can be taken from the mid-esophagus for additional evaluation.
    - Must be symptomatic at Visit 1 (run-in period) and Visit 2 (randomization):
    (a) A patient reported average of at least 2 days per week with an episode of dysphagia over the 4 weeks prior to the run-in period AND
    (b) At least 2 days with an episode of dysphagia (Daily DSQ =2) per week between Visit 1 and the Visit 2 (randomization).
    - Must be adherent to daily diary assessments:
    (a) Must complete 70% of daily diaries between Visit 1 and Visit 2; AND
    (b) Must have completed at least 8 of 14 daily diaries in the 14 days prior to randomization.
    - May be on background medications for EoE and related treatments during the study as long as the background medications have been stable for at least 4 weeks prior to the run-in period.
    - Body weight of at least 35 kg.
    - Negative serum pregnancy test for female patients of childbearing potential at Visit1.
    - Women of childbearing potential must agree to use a highly effective form of birth control (confirmed by the Investigator) from randomization throughout the study duration and within 16 weeks after last dose if IP.
    ­- Pazienti tra i 12 e 65 anni di età inclusi, al momento della firma del modulo di consenso informato o dell’assenso (se applicabile).
    ­- Diagnosi di Esofagite eosinofila precedentemente documentata tramite endoscopia (la diagnosi documentata è definita come conta esofagea = 15 eos/hpf su almeno 1 livello esofageo) e diagnosi confermata da una biopsia esofagea letta a livello centrale allo scopo del presente studio (la diagnosi confermata è definita come conta esofagea = 15 eos/hpf su 2 o più livelli esofagei). Dovrebbero essere ottenute da 2 a 4 biopsie sia dalla pozione prossimale che distale dell’esofago. Per valutazioni aggiuntive possono essere fatte delle biopsie dalla porzione centrale dell’esofago.
    ­- I pazienti devono essere sintomatici alla visita 1 (periodo di “run-in”) e visita 2 (randomizzazione):
    a) una media riportata dal paziente di almeno 2 giorni a settimana con episodi di disfagia nelle 4 settimane precedenti il periodo di “run-in” E
    b) almeno 2 giorni con un episodio di disfagia (DSQ giornaliero =2) per settimana tra la visita 1 e la visita 2 (randomizzazione).
    ­- I pazienti devono essere aderenti alle valutazioni giornaliere del diario:
    a) Devono completare il 70% dei diari giornalieri tra la visita 1 e la visita 2; E
    b) Devono avere completato almeno 8 dei 14 diari nei 14 giorni antecedenti alla randomizzazione.
    ­- I pazienti devono essere in trattamento di base per l’Esofagite eosinofila e usare trattamenti correlati durante lo studio fino a quando i farmaci di base sono stabili per almeno 4 settimane prima del periodo di “run-in”.
    ­- Peso corporeo di almeno 35 Kg.
    ­- Test di gravidanza negativo su siero per pazienti donne in età fertile alla visita 1.
    ­- Donne in età fertile devono accondentire ad utilizzare un metodo contraccettivo altamente efficace (confermato dal ricercatore) dalla fase di randomizzazione, durante tutta la durata dello studio ed entro 16 settimane dopo l’ultima dose dell’IP.
    E.4Principal exclusion criteria
    - Other GI disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, or celiac disease.
    - Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation during the run-in period.
    - Use of a feeding tube, or not eating solid food daily during the run-in period.
    - Hypereosinophilic syndrome, defined by multiple organ involvement and persistent blood eosinophil count >1500 eos/µL.
    - EGPA vasculitis.
    - Eosinophilic gastritis, gastroenteritis, enteritis, or colitis documented by biopsy.
    - Current malignancy, or history of malignancy with some specific exceptions.
    - History of anaphylaxis to any biologic therapy or vaccine.
    - Current active liver disease:
    * Chronic stable hepatitis B and C (including positive testing for hepatitis B surface antigen [HBsAg] or hepatitis C antibody), or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria.
    *Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level =3 times the upper limit of normal (ULN), confirmed by repeated testing during the run-in period.
    - Helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent or assent (if applicable) is obtained that has not been treated with or has failed to respond to standard of care therapy.
    - History of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.
    - Concomitant use of immunosuppressive medication.
    - Initiation or change of a food-elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to start of the run-in period.
    - Currently pregnant, breastfeeding, or lactating women.
    ­- Altri disturbi gastrointestinali come l’infezione attiva da Helicobacter pylori, storia di acalasia, varici esofagee, morbo di Crohn, colite ulcerosa, malattie infiammatorie croniche intestinali, o celiachia.
    ­- Restringimento dell’esofago che impedisce il passaggio facile di un endoscopio standard o qualsiasi restringimento critico dell’esofago che richiede la dilatazione durante il periodo di “run-in”.
    ­- L’uso di un tubo per l’alimentazione, o l'impossibilità di assunzione giornaliera di cibo solido durante il periodo di “run-in”
    ­- Sindrome ipereosinofila, definita dal coinvolgimento di più organi e conta di eosinofili nel sangue persistente di = 1500 eos/uL
    ­- Vascolite EGPA
    ­- Gastrite eosinofila, gastroenterite, enterite o colite documentate tramite biopsia.
    ­- Presenza di tumore o anamnesi tumorale con alcune eccezioni specifiche.
    ­- Storia di anafilassi a qualsiasi terapia biologica o vaccini.
    ­- Malattia epatica attiva attuale:
    * Epatite B e C cronica stabile (inclusi test positivi per l’antigene di superficie dell’epatite B [HBsAg] o anticorpi contro l’Epatite C) o altre malattie epatiche croniche stabili sono considerate accettabili se il paziente soddisfa altrimenti i criteri di idoneità.
    * Livelli di alanina aminotransferasi (ALT) o aspartato aminotransferasi (AST) = 3 volte i livelli superiori di normalità (UNL), confermati da test ripetuti durante il periodo di “run-in”.
    ­- Infezione parassitaria da elminti diagnosticata entro 24 settimane prima della data in cui sia stato ottenuto il consenso informato o l’assenso (se applicabile), che non sia stata trattata o non abbia risposto alla terapia di cura standard.
    ­- Storia di disturbi da immunodeficienza noti incluso un test positivo per il virus dell’immunodeficienza umana (HIV).
    ­- Uso contemporaneo di farmaci immunosoppressivi.
    ­- Inizio o modifica di una dieta con privazione di cibo o reintroduzione di una tipologia di cibo precedentemente eliminato nelle 6 settinane precedenti l’inizio del periodo di “run-in”.
    ­- Donne al momento incinte, in allattamento al seno o in lattazione.
    E.5 End points
    E.5.1Primary end point(s)
    Dual-primary Endpoints:
    - Proportion of patients with a histologic response at Week 24, defined as a peak esophageal intraepithelial eosinophil count = 6 eos/hpf
    - Changes from baseline in DSQ score at Week 24
    End point primari:
    ­- Proporzione di pazienti con una risposta istologica alla settimana 24, definita come picco nella conta di eosinofili esofagei intraepiteliali = 6 eos/hpf
    ­- Modifiche rispetto al basale del punteggio DSQ alla settimana 24
    E.5.1.1Timepoint(s) of evaluation of this end point
    Both at Week 24
    Entrambi alla settimana 24
    E.5.2Secondary end point(s)
    Study Objectives for the DB treatment period:
    - Key secondary endpoint: Changes from baseline in centrally-read EoE EREFS at Week 24
    - Centrally-read biopsies for additional histopathology and tissue eosinophil counts, including EoE-HSS, at Week 24
    - Dysphagia-free days as captured by the DSQ
    - Frequency of dysphagia episodes as captured by the EoE-3D
    - Changes from baseline in dysphagia associated pain, discomfort, and overall severity as captured by the EoE-3D at Week 24
    - Changes from baseline in abdominal pain and nausea as captured by the daily diary at Week 24
    - Changes from baseline in EoE-QoL-A at Week 24
    - SF-36 v2 Health Survey at Week 24
    - Percent of patients with relevant concomitant procedures and healthcare resource utilization during the study through Week 24
    - PGI-S at Week 24
    - PGI-C at Week 24
    - Serum benralizumab concentration
    - ADA and nAb
    - Safety and tolerability will be evaluated in terms of AEs, Vital signs, and Clinical laboratory values
    Obiettivi di studio per il periodo di trattamento in doppio cieco:
    ­- Endpoint chiace secondari: Modifiche rispetto al basale in EREFS per Esofagite eosinofila letti centralmente alla settimana 24
    ­- Biopsie lette centralmente per istopatologia e conte di eosinofili tissutali aggiuntive, inclusi EoE-HSS, alla settimana 24
    ­- Giorni liberi da disfagia come acquisiti da DSQ
    ­- Frequenza di episodi di disfagia, come acquisito da EoE-3D
    ­- Modifiche rispetto al basale nel dolore associato a disfagia, malessere, e gravità generale, come acquisito da EoE-3D alla settimana 24
    ­- Modifiche rispetto al basale nel dolore addominale e nausea, come acquisito dal diario giornaliero alla settimana 24
    ­- Modifiche rispetto al basale nel EoE-QoL-A alla settimana 24
    ­- SF-36 v2 Health Survey alla settimana 24
    ­- Percentuale di pazienti con procedure concomitanti rilevanti e utilizzo di risorse del sistema sanitario durante lo studio fino alla settimana 24
    ­- PGI-S alla settimana 24
    ­- PGI-C alla settimana 24
    ­- Concentrazione di Benralizumab nel siero
    ­- ADA e nAb
    ­- Sicurezza e tollerabilità saranno valutate in termini di eventi avverti (AE), segni vitali e valori clinici di laboratorio
    E.5.2.1Timepoint(s) of evaluation of this end point
    Varies depending on the endpoint/objective
    Varia a seconda dell’ endpoint/obiettivo
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Samples collected for the Genomics Initiative are considered primary use and will be whole exome or whole genome sequenced. Analysis will be performed for both known and novel health related genes and this broad genetic research will not restrict to disease or drug. Sequencing data generated is for research purposes only and cannot be used for clinical decision making and there will not be any clinical endpoints delivered to the study, as a result of testing performed.
    I campioni raccolti per la “Genomic Initiative” sono considerati di uso primario e saranno sequenziati come intero esoma o intero genoma. Sarà eseguita un’analisi sia dei geni conosciuti che nuovi legati alla salute e questa ampia ricerca genetica non sarà ristretta alla patologia o al farmaco. I dati di sequenziamento generati sono esclusivamente a fine di ricerca e non possono essere usati per prendere decisioni di tipo clinico e non ci sarà alcun endpoint clinico fornito allo studio, a seguit
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    In seguito al trattamento in doppio cieco, i pazienti continueranno col Regime di Dose 1 di Benraliz
    Following DB treatment,patients will continue with Open Label benralizumab DosingRegimen1 to Week 52
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA39
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Israel
    Russian Federation
    United States
    France
    Germany
    Italy
    Netherlands
    Poland
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study is defined as the last expected visit/contact of the last patient undergoing the study.
    La fine dello studio è definita come l’ultima visita/contatto atteso dell’ultimo paziente in studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 40
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 130
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 107
    F.4.2.2In the whole clinical trial 170
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Upon completion of the initial 52-week treatment period, patients will be invited to an additional 52-week Open Label Extension of benralizumab Dosing Regimen 1 for an another 52 weeks, with ongoing study assessments. After completion of the study, patients will exit the trial and will return to care under their clinician's direction.
    Dopo il completamento del periodo iniziale di trattamento di 52 settimane, i pazienti saranno invitati ad un’aggiuntiva estensione in aperto del Regime di Dose 1 per 52 settimane ulteriori, con delle valutazioni dello studio in corso. Dopo il completamento dello studio, i pazienti usciranno dalla sperimentazione e torneranno alla cura sotto la guida del proprio medico.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-05-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-04-07
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2022-10-25
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 06:15:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA